Form 4: Alto Neuroscience CFO Granted 200,000 Stock Options

Alto Neuroscience, Inc.'s Chief Financial Officer and Chief Business Officer, Nicholas Conrad Smith, was granted 200,000 employee stock options.

Summary

• Nicholas Conrad Smith, Chief Financial Officer and Chief Business Officer of Alto Neuroscience, Inc. (ANRO), was granted 200,000 employee stock options.
• The options have an exercise price of $16.71 per share.
• The transaction date for this grant was February 11, 2026.
• The options will vest 25% on February 11, 2027, with the remaining shares vesting in monthly installments of 1/48th thereafter, contingent on continuous service.
• The options are set to expire on February 10, 2036.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it aligns the Chief Financial Officer's long-term incentives with shareholder value through equity ownership, which is generally favorable for corporate governance and performance.

Positives

• The grant of 200,000 employee stock options to a key executive like the CFO aligns management's long-term interests with those of shareholders.
• The use of a Rule 10b5-1(c) plan indicates a pre-arranged and transparent approach to executive equity compensation.

Negatives

• Stock options do not guarantee value and their ultimate benefit to the executive and alignment with shareholders depend on the company's future stock performance.

Risks

• The value of the stock options is subject to the future market price fluctuations of Alto Neuroscience, Inc.'s common stock.
• Vesting of the options is contingent upon the reporting person's continuous service through each vesting date, posing a risk if employment ceases.
• The exercise price of $16.71 means the options will only be 'in the money' if the stock price rises above this level.

Future Outlook

The grant of these stock options provides a long-term incentive for the Chief Financial Officer, aligning their future financial interests with the company's stock performance and growth over the next decade, subject to vesting conditions.

Industry Context

StockSavvy.ai notes that equity grants are a common and effective form of executive compensation in the biotechnology and neuroscience sectors. These grants are designed to align management incentives with shareholder value creation, encouraging long-term strategic decisions that benefit the company's stock price.

Comparison to Industry Standards

• StockSavvy.ai notes that grants of this magnitude (200,000 options) are typical for C-suite executives in growth-stage biotech companies, comparable to grants seen at companies like Biogen or Sage Therapeutics for similar roles.
• The vesting schedule, with an initial cliff and subsequent monthly installments over several years, is a standard practice in the industry to ensure executive retention and incentivize sustained performance.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term shareholder value.
• Employees: The grant serves as a form of compensation and retention for a key executive, potentially boosting morale and commitment within the leadership team.

Next Steps

• The options will begin vesting on February 11, 2027, with subsequent monthly vesting installments.
• The reporting person may choose to exercise the options at any time after vesting and before the expiration date of February 10, 2036, assuming the stock price is favorable.

Key Dates

Keywords

Alto Neuroscience, ANRO, Stock Option, CFO, Executive Compensation, Form 4, Insider Transaction, Equity Grant, Rule 10b5-1